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ABSTRACT

Liu, Langni. Ph.D., Biomedical Sciences Ph.D. Program, Wright State University,
2020. Ultraviolet-B radiation induces release of bioactive microvesicle particles in
keratinocytes via platelet activating factor and acid sphingomyelinase.
Ultraviolet-B (UV-B) radiation is one of the most common environmental factors
and is known to induce the production of bioactive agents that cause several
diseases including skin cancer. UVB exposure stimulates the production of a
phospholipid activator, platelet-activating factor (PAF), and its analogs in
keratinocytes that activate the PAF receptor (PAF-R) resulting in acute
inflammatory and delayed systematic immunosuppressive effects. However, as
UVB only penetrates into the skin epidermal layer, the detailed mechanisms of
how UVB exerts systematic effects remains unclear. Previously we found that
UVB induces keratinocytes to release large numbers of microvesicle particles
(MVPs). These small membrane-bound particles are released from cells via an
acid sphingomyelinase dependent lipid pathway and able to stably transfer signal
molecules from cell to cell. As PAF-R activation could regulate acid
sphingomyelinase enzymatic activity, we assessed the releasing pathway of
UVB-induced keratinocyte MVPs requires PAF-R activation and acid
sphingomyelinase in keratinocyte cell lines in vitro, human skin explants ex vivo
and mice skin in vivo. We identified the calcium-sensing receptor (CaSR) as a
marker for the detection of keratinocyte-derived MVPs in skin blister fluids and
iii

blood plasma. The enhanced CaSR-positive MVPs in blood plasma indicating
that UVB-induced keratinocyte MVPs travel systemically from the epidermis. We
detected low levels of most pro-inflammatory cytokines but found PAF like lipids
can be stably carried and transferred by these UVB induced MVPs. The MVP
carried PAF like lipids activate PAF-R in target cells result in skin inflammation.
Finally, we found that UVB does not generate systemic immunosuppression in
mice lacking aSMase which is associated with blocked MVP release, revealing a
potential mechanism that UVB mediated immunosuppression is due to MVP
systematically transferring PAF-R agonistic lipids. Though MVP is the key
transporter, blockage of MVP release could have potential therapeutic effects on
the UVB-induced inflammation and immunosuppression.
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Chapter 1. INTRODUCTION
1.1 Sunlight and ultraviolet radiation
In the early 19th century, people believed that the sunburn effects were only due
to the heat generated by sunlight. It was found by Dr. E.Holmes that simply
preventing sunlight direct exposure to the skin sufficiently blocked the sunlightinduced erythema, blistering and pain while the surrounding temperature
remained the same1. This is the first demonstration that sunlight itself can
penetrate the skin and causes biological effects. The Ultraviolet (UV) radiation
emitted by the sun can be divided into 3 subtypes: UVC (100–290 nm), UVB
(290–320 nm), and UVA (320–400 nm). Most of the UV radiation that does reach
the earth's surface is UVA (≈ 95%) and about 5% is UVB. Human skin contains a
variety of macromolecules including RNA, DNA, and proteins that can efficiently
absorb UVB radiation and less likely to absorb UVA radiation. Therefore, almost
all of the UVB is absorbed in the epidermis and only UVA can penetrate deeper
into the skin reaching the dermal layers 2, 3. Once UV has been absorbed by
epidermal cells, it induces the formation of various molecules that causes
cutaneous inflammation, immunosuppression, and skin cancers.

In 1922, Hess and Unger reported that sunlight exposure could benefit bone
disease treatment4. Quickly, a new form of vitamin D found been produced by the
skin when exposed to sunlight was associated with this effect, later been
identified as vitamin D3 (VD3) by Windaus et al5. During sunlight exposure,
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epidermal cells absorb UVB radiation and induce the precursor of VD3
production and rapidly convert into VD3 in few hours in the plasma. Once
formed, VD3 transports to the liver where it is converted to the circulating form of
VD3, the 25-hydroxyvitamin D36. The circulating VD3 can travel to many tissues
including the brain, breast, prostate, skin, and kidney where it is converted to the
active form 1,25-dihydroxyvitamin D37. The activated VD3 interacts with cell
nuclear receptors can regulate numerous physiological processes including DNA
repair, antioxidant activity, immunity, cell growth, differentiation, and
cardiovascular regulation8, 9.

1.2 Inflammatory responses to ultraviolet-B radiation
The best-known acute effect of excessive UV exposure is sunburn (erythema),
which is an acute inflammatory reaction of the skin associated with redness,
pruritus, and pain. The initial inflammatory response of UV irradiation caused
erythema is due to vasodilated blood vessels in the skin. Many factors have been
reported to mediate UV induced erythemal response, yet most of them had only
minor responses. Antagonists of H1 and H2 histamine receptor increase vascular
permeability and vasodilate cutaneous blood vessels indicate the role of
histamine in UV induced initial inflammation, but blockage of histamine receptor
has no effects on prolonged inflammatory responses10. The increase of
prostaglandin (PG) synthases including PGE2 and PGJ2 occurs 24 hours post
UVB treatment and is related to upregulated cyclooxygenase-2 (COX-2) mRNA
and protein level11. The specific COX-2 inhibitor, Celecoxib, can inhibit acute
2

UVB-induced cutaneous inflammatory response via reduced edema, dermal
myeloperoxidase activity, neutrophil infiltration12. Inhibitors of PG synthesis are
also noted to decrease the erythemal response but could not eliminate it13, 14.
Keratinocytes produce nitric oxide (NO) after UVB irradiation also known to be a
potent vasodilator15, indicating that targeting NO synthases might be able to
regulate UVB induced inflammatory responses. Besides vasodilation induced
edema, other inflammatory substances, including inflammatory cytokines, may
have minor, but still important roles.

When exposed to UVB, the major cell line in the epidermis, keratinocytes,
produce cytokines including transforming growth factor-alpha (TGF-α),
transforming growth factor-beta (TGF-β), macrophage colony-stimulating factor
(M-CSF), interferon-gamma (INF-γ), interleukin-1 alpha (IL-1α), interleukin-1 beta
(IL-1β), interleukin-3 (IL-3), granulocyte colony-stimulating factor (G-CSF), and
platelet-derived growth factor (PDGF) which are involved in UVB induced
inflammatory responses16, 17. UVB can induce nuclear factor κB (NFκB) that
leads to the production of the pro-inflammatory cytokines interleukin-1 (IL-1),
interleukin-6 (IL-6), interleukin-8 (IL-8), and tumor necrosis factor-alpha (TNFα)18. These pro-inflammatory cytokines generated in UVB affected areas cause
local cutaneous inflammation via affected leukocyte margination, endothelial
adhesion, and macrophage activation.
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1.3 Immunosuppressive effects of ultraviolet-B radiation
In 1963 Hanisko and Suskind observed that skin exposed to UVB reduced the
contact hypersensitivity response in skin sensitized to dinitrochlorobenzene19.
This is the first study of UVB-induced immune responses. Based on this initial
observation, scientists found that UV-induced tumor growth was highly
associated with systematic alteration of the immune system, and tumors can only
be transplanted to immunosuppressed hosts20, 21. Thus, UVB-induced
immunosuppression contributes to skin cancer progression.

In 2011, the melanoma incidence rate in the USA was 19.7 per 100,000 and still
continuous increase through 2019 with about 9,000 persons dying from it each
year22. The estimated nonmelanoma skin cancer patients in the U.S. population
is more than 5 million in 2012 and increased by 13% from 2006 to 201223. UV
induced DNA mutations represent the major causative factor for skin cancers.
UVB-induced immunosuppression is triggered by DNA damage generated
cyclobutane pyrimidine dimers (CPD) or thymine dimers24. The formation of
CPDs enhances immunosuppressive cytokines, IL-1025 and TNF-α26, and
triggers the development of regulatory T cells (Treg) result in downregulation of
type 1 T helper cell (Th1) mediated immune responses 27, 28, and impairs the
ability of antigen-presenting cells such as Langerhans cells in the epidermis to
present antigen properly which results in an overall lack of immune
sensitization29.

4

Accumulating evidence demonstrates that COX-2 - PGE2 is also involved in UVB
induced immune suppression. UVB-induced COX-2 expression and PGE2
production human and murine dendritic cells involved in immune suppression via
regulation of Treg differentiation30. Inhibitor of COX-2 shown to prevent UVB
induced immune suppression31, 32. COX-2 deficient mice were resistant to UVB
induced suppression of the CHS response, whereas the treatment of PGE2
restored the immunosuppression in UVB irradiated COX-2 deficient mice31. COX2 expression and PGE2 production can be upregulated by platelet-activating
factor (PAF) in keratinocytes33, which produced rapidly after UVB exposure34.

1.4 Platelet-activating factor
Platelet-activating factor (PAF; 1-0-alkyl-2-acetyl-sn-glycero-3-phosphocholine) is
a pro-inflammatory phospholipid with diverse potent physiological effects in
platelet aggregation, inflammation, and allergic response19. PAF is a group of
glycerophosphocholines (GPC) with an ether bond at the sn-1 position, an
acetate residue at sn-2 position, and a phosphocholine head group at sn-3
position on the glycerol backbone35. Lipid compounds with similar structures with
different lengths of the alkyl chain at the sn-2 position refer to PAF analogs. They
may have similar effects but are usually less potent than PAF. PAF binds to the
PAF receptor (PAF-R), which constantly expressed by endothelial cells and
keratinocytes36-38. UVB induced formation of oxidized-GPCs (ox-GPCs) with free
radical mediated oxidative cleavage of the sn-2 fatty acid can also activate PAFR, which refers to PAF-R agonistic lipids39-41. Our group analyzed some of the
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structures of these ox-GPCs by mass spectrometry, but many still remained
uncharacterized41. The PAF-R is also activated by the carbamyl-plateletactivating factor (1-hexadecyl-2- N-methylcarbamyl-glycero-3-phosphocholine; CPAF), a functional analog of PAF. Unlike PAF, which is quickly broken down, CPAF is non-metabolizable that can be used as a stable PAF agonist including in
ex vivo studies42.

PAF is synthesized by various cell types including platelets, macrophages,
monocytes, and endothelial cells by specific stimulation43. There are two distinct
pathways for PAF synthesis (Figure 1). The first is the remodeling pathway
initiated with a long-chain fatty acyl residue in sn-2 is replaced with an acetyl
residue. This pathway is involved in allergic and inflammatory responses when
cell stimulated by specific stimulus44. The second is the de novo synthesis
pathway that a phosphocholine is transferred to alkyl acetyl glycerol. This
pathway is physiologically important in maintaining steady state levels of PAF in
various tissues and blood45, 46.

When the cell is stimulated, PAF synthesis initiated by the arachidonate specific
cytosolic phospholipase A2 (cPLA2) hydrolyzes arachidonate from 1-alkyl-2arachidonoyl-sn-glycero-3-phosphocholine generating the inactive form 1-alkyl-2lyso-sn-glycero-3-phosphocholine (lyso-PAF) and free arachidonic acids47, 48.
The lyso-PAF can then be acetylated by acetyl CoA-lyso-PAF acetyltransferase
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(lyso-PAF-AT) to form PAF35, 49. The de novo pathway requires the participation
of three enzymes: 1-alkyl-2-lyso-sn-glycero-3-phosphate (alkyllyso-GP): acetylCoA acetyltransferase, 1-alkyl-2-acetyl-sn-glycero-3-phosphate
phosphohydrolase, and dithiothreitol (DDT)-insensitive 1-alkyl-2-acetyl-snglycerol (alkylacetyl-G):CDP-cholinecholinephosphotransferase (PAF-CPT). PAF
produced by PAF-CPT hydrolysis of acetate from 1-alkyl-2-acetyl-sn-glycerol50,
51

. The enzymes in this pathway are apparently constitutively active and seem to

be regulated largely by the availability of substrate. The remodeling pathway is
the major route for PAF production in inflammatory and allegoric responses. The
de novo pathway had minor effects on PAF synthesis in some studies52 and
provides an alternative way to from PAF under cell stimulation.

PAF made by either pathway is degraded to the inactive product by one of a
family of phospholipases, the PAF acetyl hydrolases (PAF-AH) catalyzes the
hydrolysis of short acyl groups at sn-2 position of PAF as well as phospholipids
containing oxidatively fragmented sn-2 fatty acyl groups to from lyso-PAF,
indicated that PAF-AH not only degrades PAF and its analogs, may also function
in other PAF-R agonistic lipids.
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Remodeling pathway
Alkyl-acyl-GPCs

De novo pathway
Alkyl-lyso-glycerophosphate (ALPA)
ALPA-AT

cPLA2

Alkyl-acetyl-glycerophosphate
Lyso-PAF

Phosphohydrolase

lyso-PAF-AT

Alkyl-acetyl-glycerol
PAF-CPT

Platelet-Activating Factor
PAF-AH
Lyso-PAF
Degradation pathway

Figure 1. Biosynthesis and degradation of PAF. Details see in text above.
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1.5 Signal transduction from platelet activating factor
Under normal circumstances PAF is not found in the skin, however, keratinocytes
can synthesize PAF in response to a variety of stimuli such as ionophores,
growth factors, PAF agonists, oxidative stress, ultraviolet radiation, and prooxidant lipid tertiary butyl hydroperoxide53, 54. PAF binds to the specific
membrane receptor PAF-R that is a single 7-transmembrane G-coupled protein
receptor. Binding of PAF to membrane PAF-R stimulates GTPase activity,
activates phosphatidylinositol-specific phospholipase C (PI-PLC) results in
transient production of inositol trisphosphate (IP3) and diacylglycerol (DAG). IP3
mediates the release of internal calcium stores, which is followed by an influx of
extracellular calcium. These changes activate protein kinase C (PKC), which
catalyzes the phosphorylation of target proteins38. Activation of PKC in turn
downregulates PAF-R expression, activates cPLA2 to mediate PAF synthysis55.

PAF stimulates all three extracellular signal-regulated kinase (ERK), c-JunNH(2)-terminal kinase (JNK), and p38 mitogen-activated protein kinases (p38
MAPK)56, 57. Inhibitors of all three kinases either partially or completely protected
mice against PAF induced death56. Inhibition of JNK, and p38 MAPK attenuates
PAF induced platelet aggregation in human platelets56. PAF induced proinflammatory cytokine expression blocked by inhibitors of ERK and p38 MAPK in
airway smooth muscle cells57. Besides increased phosphorylation of ERK1/2
MAPK in adenocarcinoma cells, PAF induced cPLA2 phosphorylation was also
associated with activation of ERK1/2 MAPK58. The apoptotic signal caspase-3
9

was found elevated in cardiac myocytes treated with PAF, this PAF-induced
enhancement of caspase-3 activity and release of cytochrome c from
mitochondria was attenuated by p38 MAPK inhibitor, indicated the involvement of
p38 MAPK and caspase-3 in PAF associated apoptotic responses59. All these
lines of evidence suggest that MAPK and cascade signal pathways are the
downstream targets of PAF-R activation in inflammatory and apoptotic
responses.

1.6 Ultraviolet-B radiation and platelet-activating factor
UVB-irradiation of keratinocyte activates the generation of reactive oxygen
species (ROS) that promote the photoperoxidation of polyunsaturated cellular
phospholipids. Oxidation of the esterified fatty acyl residues promotes the
generation of PAF and PAF-like lipids in a non-enzymatic way40, 60. ROS
mediated PAF-R agonistic lipids formation has also shown to be associated with
the epidermal growth factor receptor (EGF-R) activation. The in vivo production
of PAF was blocked by both systemic administration of the antioxidant vitamin C
(VC) and topical treatment with an inhibitor of EGF-R in UVB irradiated mice61.
Similar results were also found in human skin when treated with antioxidant VC
and EGF-R inhibitors topically34. The ROS mediated PAF production suggested
an important mechanism for initiating the immunosuppressive pathway induced
by UVB.
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Once PAF-R activated by UVB, the keratinocyte PAF-R stimulates the production
and release of the inducible form of COX-2, PGE2, pro-inflammatory cytokines
TNF-α, IL-6,and IL-8, immune-regulatory cytokines IL-10 and IL-33 and PAF like
lipidis33, ultimately result in the activation of several signaling. After UVB
exposure, dermal mast cells quickly accumulated in UVB exposed skin area in an
IL-33 dependent manner62. After 24 hours, Mast cell density in skin returned to
normal where it significantly increased in the skin draining lymph nodes (LNs)63.
A study using green fluorescent protein-positive mice confirmed that they were
migrated from the skin into LNs after UVB treatment64. Elevated C–X–C
chemokine receptor type 4 (CXCR4) expression on the mast cell surface was
found after UVB radiation63. Inhibition of CXCR4 blocked mast cell migration and
UVB-induced CHS responses63, 65. These evidences suggest that mast cell
migration is a key factor in transferring immune suppressive signals from skin to
the immune system.

UVB-induced PAF formation has been shown to trigger mast cell migration.
Injection of PAF-induced mast cell migration in WT mice, but not in PAF-R
deficient mice. UVB mediated inhibition of CHS is only presented in WT mice, not
in PAF-R deficient mice65. Treatment of PAF resulted in increased CXCR4 on
mast cells and its ligand, CXCL12 in draining LNs66. Injection of CPAF in WT
mice resulted in increased CXCL12 expression in LN cells where CXCL12 had
no change in PAF-R deficient mice66. In summary, PAF regulates mast cell
migration dependent on CXCL4 and CXCL12. Once mast cells arrive at the
11

draining LNs, they release IL-10 to mediate antigen formation in T cells67, 68. IL10 downregulates Th1 effector memory cell radiated immune responses.
Injection of IL-10 from UV irradiated keratinocytes to splenic antigen-presenting
cells caused inhibition of antigen presentation to Th1 cells and enhanced
stimulation of type 2 T helper cell (Th2) mediated responses, treatment of anti-IL10 neutralized UVB induced suppressive effects and restored antigen-presenting
cell function69 indicated its important role in regulating immune responses. PAF
activates transcription of the IL-10 promoter70. Injection of neutralizing anti–IL-10
antibody in WT mice blocked CPAF induced CHS response71. UVB induced PAFR activation upregulates IL-10 by induced transcription of COX-2 and secretion of
PGE271, suggests that PAF mediated UVB immunosuppression is through
induction of IL-10.

Though UVB irradiation only exposes the epidermis of the skin, this
environmental stressor can cause systematic effects. UVB induces PAF-R
activation in keratinocytes, yet how it affected dermal cells remain unclear.
Previously we reported that both UVB irradiation and CPAF treatment can
stimulated microvesicle particle (MVP) release in keratinocytes and human skin
blister fluids72. MVP is a key message transporter in the cellular communication
process. We believe that this UVB-induced mediator plays an important role in
transfer cytokines and bioactive lipids from the skin epidermis to all other cells
finally resulted in systematic effects.
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1.7 Key features of microvesicle particles
Microvesicle particles (MVP), also named as microvesicles and microparticles,
are small membrane-bound particles with a diameter between 100-1000 nm that
directly shed from the plasma membrane of virtually all eukaryotic cells. MVPs
contain a variety of bioactive substances such as proteins, bioactive lipids,
cytokines, nucleic acids as their contents, and abundant membrane receptors
and adhesion molecules on the surface73. As depicted in Figure 2, once they are
released by the parental cells, MVPs can transfer biological information from
parental cells with direct fusion or internalization into the target cells and transfer
content molecules or through activation of membrane receptors74-76.

Figure 2. Biogenesis of
microvesicle particle
(MVP). Microvesicle
particles are directly
budded from plasma
membrane which carry
various signal molecules
including nucleic acids,
proteins, and lipids.
(Images adapted from
Słomka et al., 201877)
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MVP derived from different parental cells can exert their respective functions. For
example, MVPs derived from indolent glioma cells containing the oncogenic form
of epidermal growth factor receptor, these particles released in blood merge with
other cells lacking the oncogenic receptor, leading to transferred oncogenic
activity with activation of transforming signaling pathways and changes in
oncogenic receptor gene expression in target cells78. Embryonic stem cellderived MVPs carry laminin and fibronectin which interact with integrins along the
surfaces of the target cell trophoblasts. This communication triggers trophoblast
migration, and JNK activation results in induced embryo implantation79. Plateletderived MVPs can transfer their contents including platelet-derived bioactive lipid
mediators, cytokines, mRNAs, and microRNAs to cells across the entire
circulatory system which may mediate inflammatory responses and contribute to
exacerbating inflammatory diseases and conditions80.

1.8 Releasing mechanism of microvesicle particles
Despite the growing understanding of the MVP functions, the formation and
releasing mechanisms of MVP remain incompletely understood. MVP biogenesis
requires several molecular rearrangements within the plasma membrane,
including changes in lipid components and protein composition and Ca2+ levels.
Ca2+ dependent enzymatic machineries including aminophospholipid
translocases (flippases and floppases), scramblases, and calpain81, 82. The
increased concentration of Ca2+ activates scramblase and calpain leads to the
exposition of phosphatidylserine from the inner leaflet to the cell surface which
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causes physical bending of the membrane the reorganization of the
cytoskeleton82. Ca2+ mediated activation of PKC by phorbol esters also known to
regulate MVP release83. The activity of the Rho family of small GTPases is
important regulators of actin dynamics mediated induction of microvesicle
biogenesis in tumor cells81, inhibition of Rho GTPases activity blocks MVP
biogenesis in breast cancer cells84.

Several studies have reported that MVP regulation was associated with ATPdependent receptor P2X7-R85, 86. P2X7-R mediated MVP shedding is preceded
by exposure of phosphatidylserine (PS) at the cell surface, loss of plasma
membrane asymmetry, and formation of the membrane protrusions. It has been
found earlier that upon activation of the ATP receptor P2X7-R, MVP shedding is
associated with rapid activation of specific sphingomyelinase, acid
sphingomyelinase (aSMase), which moves to plasma membrane outer leaflet
from lysosome85. The generation of ceramide by sphingomyelin hydrolysis,
catalyzed by the enzyme aSMase, results in the increased efflux of cholesterol
and increased membrane fluidity, thus inducing membrane destabilization and
facilitating membrane blebbing and MVP shedding87. It has also been reported
that aSMase-induced MVP release increased inflammatory cytokines in MVP88.
Complete blockade of MVP shedding and cytokine release from aSMase knockout (KO) astrocytes indicates that the release of MVP from the plasma
membrane represents the major mechanism mediating secretion of the cytokine
from glial cells86. The aSMase inhibitor, imipramine has also been found to
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sufficiently blocks osteoblast-derived MVPs89. Therefore, MVP releasing via
aSMase-ceramide pathway has considered a very important general lipid
pathway and it may alter the MVP contents.

1.9 Ultraviolet radiation associated microvesicle particles
Though MVP has been examined in the context of various disease states ranging
from cardiovascular disease to cancers, the concept of MVP as a transmitter of
systemic signals from keratinocyte following a cutaneous insult such as UVB is
yet unexplored.

UV treatment on platelet concentrates triggers mitochondrial translocation,
cytochrome c release, and MVP release in a p38 MAPK dependent manner90.
UV exposure stimulated MVP production in prostate cancer cells is a source of
the DNA damage-induced bystander effect that UV-induced DNA damage
responses not only in cells that are directly exposed but also in cells that are not
directly affected91. UV radiation led to the production of antigenically active
particles in peripheral blood leukocytes that display DNA and nucleosomal
molecules which mediate immune responses in Systemic Lupus
Erythematosus92. UVB irradiated dermal fibroblasts MVPs are rich in various
miRNAs and proteins. Their contents are linked to a broad range of biological
functions, including fibroblast proliferation, UV protection, collagen biosynthesis,
DNA repair, and cell ageing93. UV induced MVPs can transfer from melanocytes
to keratinocytes, which may contribute to skin pigmentation72. All these results
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implied the ability of MVP to transfer UV induced signal systematically.

We have previously found that treating keratinocyte cell line, HaCaT cells with
both CPAF and UVB results in the release of abundant MVPs72, 94. MVP released
in human skin blister fluids following UVB treatment suggested that MVP could
travel from the skin epidermis to the surrounding extracellular environment.
However, the releasing mechanism and bioactivity of keratinocyte released MVP
with UVB irradiation remain unknown. In a pulmonary edema model, PAF
induced edema is associated with increased aSMase activity and ceramide
formation95. The activation of PAF-R accumulates lysosomal aSMase translocate
to the plasma membrane where it hydrolyzes sphingolipids into ceramide.
Ceramide is the key lipid mediator to induce MVP release. However, whether
UVB induced PAF-R activation and aSMase activity is the key mechanism of
UVB released MVP in keratinocyte remains unknown. In this study, the roles of
PAF-R activation and aSMase in UVB-induced MVP release and bioactivity will
be analyzed using keratinocyte cell lines, human skin explants, mice models and
human subjects.
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Chapter 2. HYPOTHESIS AND SPECIFIC AIMS
2.1 Statement of Purpose
Ultraviolet radiation constitutes about 10% of the total light output of the Sun. It
causes sunburn effects in the skin, induces inflammation, immunosuppression,
and increases the risk of skin cancer. Ultraviolet-B (UVB) radiation can only
appreciably be absorbed by the epidermis yet induces both local and systematic
effects. Uncovering the mechanisms that contribute to systematic signal transfer
after UVB irradiation is a critical step toward better understanding the skin
disease progression. The ability of small membrane-derived MVPs to transport
bioactive molecules attracts attention in numerous diseases including
cardiovascular diseases and cancers, however, skin disease associated MVPs
are still unexplored.

To better understand the UVB-induced MVP mechanisms can potentially improve
the treatment strategies of skin diseases and even provide a new target for the
treatment. In this study, we hypothesized a potential releasing mechanism of
UVB-MVPs via PAF-R and aSMase activation. This hypothesis was tested by
keratinocyte cell lines, human skin explants, mice models, and human subjects.

Considering the important roles of MVPs in cellular communication, to further
assesses the potential immunomodulatory functions of UVB induced keratinocyte
MVPs, we detected the potential pro-inflammatory molecules carried by
18

keratinocyte-derived MVPs including cytokines, chemokines, PAF lipids, as well
as their ability to cause skin inflammation and systematic immunosuppression.

2.2 Hypothesis
We hypothesized that UVB stimulates keratinocyte to release MVPs through
PAF-R and aSMase activation (Figure 3). These MVPs can activate target cells
through transferred content molecules involved in UVB associated local and
systematic immunoregulatory effects.

MVP shedding

ASM

PAF-R

Figure 3. Proposed releasing mechanism of UVB-induced MVP shedding
via PAF-R and aSMase activation.
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2.3 Specific aims
Specific aim 1: Investigate the bioactivity of UVB-induced keratinocyte
MVP.
Aim 1.1: Analyze the UVB-stimulated MVP release in keratinocyte cell lines,
human skin explants, patient blood and mice model.
Keratinocyte cell lines HaCaT, nTERT, and primary keratinocytes, human skin
explants, and WT mice were used to test UVB-induced MVP release. Samples
were exposed to UVB light for 4 hours, then MVPs were collected from either cell
culture medium, skin blister fluids or skin tissues. MVP concentration was
measured using Nanoparticle Tracking Analysis. Patient blood was collected
from patients who received whole body UVB phototherapy before, 2 hours postor 4 hours post-treatment. MVPs were isolated from blood plasma and processed
to Nanoparticle Tracking Analysis. Keratinocyte-derived MVPs in blood sample
were determined by CaSR-positive staining using Flow Cytometry.

Aim 1.2: Measure inflammatory cytokines in keratinocyte-derived MVPs.
UVB- and CPAF-induced HaCaT MVPs were collected and analyzed for 27
human cytokines using Bio-Plex Pro™ Human Cytokine 27-plex Assay. Cytokine
level of IL-8 was double confirmed by ELISA in HaCaT cell and KBP cell.
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Aim 1.3: Detect the ability of UVB-induced MVPs to transfer inflammatory PAF
like lipids.
The ability of UVB-induced MVP to transfer PAF lipids was detected by PAF-R
activation in target cells. Lipids were extracted from either UVB treated HaCaT
cell lysate, complete cell medium, MVPs isolated from cell medium, or MVP
depleted cell medium. Lipids then added to PAF-R overexpressed KBP cells. The
released IL-8 level represents PAF-R activation in stimulated KBP cells. IL-8
released by lipids treatments were compared to positive control (CPAF)
treatment stimulated PAF-R responses.

Specific aim 2: Determine the effects of regulated aSMase activity in UVBinduced keratinocyte MVP release and its bioactivity.
Aim 2.1: Determine if UVB-induced MVP release requires aSMase activity in
keratinocyte cell lines and mice skin.
HaCaT cells and human skin explants were treated with aSMase inhibitor
imipramine immediately after UVB treatment. Besides cell and human skin
explants, aSMase KO (smpd1 -/-) mice was also used to detect UVB-induced
MVP release. Mice back skin was shaved and exposed to UVB light, MVPs were
collected 4 hours post-treatment from either cell medium or skin tissue. MVP
concentration was measured using Nanoparticle Tracking Analysis.
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Aim 2.2: Test the effects of aSMase associated MVP release inhibition on UVB
induced systematic immunosuppression.
UVB induced systematic immunosuppressive effects were determined by
Contact Hypersensitivity (CHS) Assay. Both WT and aSMase KO mice were
either exposed to UVB on shaved back skin or treated with 20 ng CPAF i.p.
injection. After 5 days, sanitizer DNFB was applied to non-irradiated back skin.
After 9 days, ear thickness was measured, then vehicle solution or sanitizer
DNFB was applied to mice ear, second ear thickness was measured after 24
hours. The ear thickness changes between sanitizer DNFB to vehicle was used
to indicate the induction of immune responses.

Specific aim 3: Determine the role of PAF-R activation in UVB-induced
keratinocyte MVP release and its bioactivity.
Aim 3.1 Determine if UVB-induced MVP release requires PAF-R activation in
keratinocyte cell lines and mice skin.
The PAF-R deficient cell line KBM and PAF-R over-expressed cell line KBP cell
were used to determine the role PAF-R activation in UVB-induced keratinocyte
MVP release. The PAF-R KO (ptafr -/-) mice was also used in this aim. MVPs
were collected 4 hours after UVB irradiation from either cell medium or skin
tissue. MVP concentration was measured using Nanoparticle Tracking Analysis.

22

Aim 3.2 Test the effects of PAF-R associated MVP release inhibition on UVB
induced inflammation and immunosuppression.
Both WT and PAF-R KO mice were used in this experiment. UVB-induced MVP
lipids and control MVP lipids were isolated and added topically to mice ears. Ear
thickness was measured both before and after treatments. An increase in ear
thickness represents the skin inflammation induced ear swelling. UVB- and
CPAF-induced immunosuppressive effects were determined by CHS reaction as
previously introduced in aim 2.2.

Aim 3.3 Test the PAF-dependency on regulating aSMase activity.
HaCaT cells were treated with either CPAF or UVB radiation, 4 hours posttreatment, the cellular protein was extracted and analyzed for aSMase enzymatic
activity.
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Chapter 3. MATERIALS AND METHODS
3.1 Cell culture
The commonly used spindle shaped human keratinocytes cell line, HaCaT cell is
the major cell model in this study. Other keratinocyte cell lines including nTERT
cells, primary keratinocytes, and the human nasopharyngeal carcinoma-derived
KB cells were also used to provide supportive evidence. The nTERT was
immortalized primary keratinocyte cell line expressing the human telomerase
reverse transcriptase hTERT. Primary keratinocytes were isolated by Dr. Kemp
following Thermo Fisher Scientific Protocol for Isolation and Culture Techniques
of Human Keratinocytes from the donated skin of abdominoplasty patients. KB
cells were derived from a patient with a nasopharyngeal carcinoma which
originally lacks PAF-R. KBP cells were KB cells transduced with MSCV2.1
retrovirus containing the PAF-R, which were PAF-R overexpressed cells. KBM
cells were KB cells transduced with the control MSCV2.1 retrovirus, which
remained PAF-R deficiency96.

HaCaT, KBP and KBM cells were grown in high glucose DMEM medium added
with 10% FCS, 100 U penicillin/0.1 mg/ml streptomycin and 2 mM glutamine.
Primary keratinocytes and nTERT cells were cultured in EpiLife medium with the
addition of Human Keratinocyte Growth Supplement (HKGS).
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3.1.1 Treatment
Cells were washed with PBS 3 times and then change to HBSS added with 10%
BSA solution for treatment. Cells were either treated with NT (no treatment), VEH
(vehicle: 0.1 % EtOH), CPAF (PAF-R agonist, 100 nM), UVB (3600 J/m2), IMIP
(aSMase inhibitor, imipramine: 50 µM) immediately after UVB irradiation, C2-C
(C2-ceramide: 20 µM) or Di-C (Dihydro-ceramide: 10 µM). After 4 hours, the cell
medium was collected for MVP isolation, cells were harvested for cell count.

3.1.2 Cell count
HaCaT, KBP/ KBM cells were trypsinized by 0.25% trypsin, primary keratinocytes
and nTERT cells were trypsinized by 0.05% trypsin. Trypinized cells were
centrifuged at 800 x rpm for 5 minutes to pellet cells. Cell pellet was resuspended with 1 ml fresh medium for cell count. Cells were stained with
propidium iodide (PI) and observed under microscopy. Unstained cells
represented live cells and PI stained cells represented dead cells. Cell viability
was counted as live cell number / total cell number x 100%.

3.1.3 Cell microvesicle particle preparation
Cell-derived MVPs were isolated from culture medium after treatments. Culture
medium were collected in microcentrifuge tubes and spin at 2,000 x g for 20
minutes to remove cell debris. The supernatant then transferred to a new
microcentrifuge tube and centrifuge at 20,000 x g for 70 minutes. The resulted
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pellet was MVP. MVP pellet was re-suspended in 100 µl filtered phosphatebuffered saline (PBS) stored in -20 °C for further analysis97.

3.2 Human skin explants
De-identified discarded skin was obtained from abdominoplasty and
brachioplasty surgeries. The skin was washed, fat trimmed, and placed in PBS
warmed at 37 °C for treatment.

3.2.1 Skin tissue biopsy sample preparation
Skin explants were cut in 2 cm x 2 cm squares (see Figure 4). The skin surface
was treated with either NT (no treatment), VEH (90% DMSO+10% EtOH), CPAF
(100 nM), UVB (3600 J/m2), IMIP (imipramine: 50 µM) immediately post-UVB
irradiation. After 4 hours, skin tissue sample was collected by punch biopsy. The
biopsied tissue was weighted, fat trimmed then cut up finely in the
microcentrifuge tube, digested in 0.5 ml of 5 mg/ml collagenase and dispase
solution made in deionized filtered water, and gently shacked overnight at 37 °C.
After overnight digestion, sample was spin at 2,000 x g for 20 minutes to remove
tissue, then followed with 20,000 x g centrifuge for 10 minutes to remove
remaining tissue and subcellular component. MVP was then pelleted after 20,000
x g centrifugation at 70 minutes from the sample supernatant. MVP pellet was resuspended in 100 µl filtered PBS and stored in -20 °C for further analysis97.
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Figure 4. Human skin explants tissue biopsy sample preparation.

3.2.2 Skin blister sample preparation
Skin blisters were generated with a Vacuubrand® vacuum pump, 100 mbar,
attached to the barrel of a 20 ml syringe72 (see Figure 5). The blisters were
induced in a fashion to separate the epidermis from the dermis. Once blisters
had formed, the barrels were removed, and the surface of blisters was treated
with either NT (no treatment) or UVB (3600 J/m2). After 4 hours, blister fluids
were collected with needle and syringe. Blister fluid volume was measured in the
microcentrifuge tube then followed with MVP isolation procedures introduced in
3.2.1.

Figure 5. Skin blister experimental model.
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3.3 Mice
Female C57BL/6 WT mice (age 6-8 week) were purchased from The Charles
River Laboratories. Age-matched PAFR KO (Ptafr-/-) mice on a C57BL/6
background, generated as previously described98, were a kind gift of professor
Takao Shimizu (Department of Biochemistry, University of Tokyo). The smpd1 +/heterozygous mice were obtained from Dr. Irina Petrache’s group at the National
Jewish Medical Center in Denver Colorado. The aSMase KO (smpd1 -/-) mice
were bred by heterozygous littermates. Each pup was genotyped by a
polymerase chain reaction (PCR) to ensure the homozygous knock-out of the
smpd1 gene. All mice were housed under specific pathogen-free conditions and
all procedures were approved by the Institutional Animal Care and Use
Committee of Wright State University.

3.3.1 Mice skin tissue biopsy sample preparation
Mice were anesthetized by Ketamine/ Xylazine (100 and 10 mg/kg, respectively)
i.p. injection. The back skin was shaved using a clipper and treated with either
SHAM (no treatment), VEH (90% DMSO+10% EtOH), CPAF (PAF-R agonist,
100 nM), UVB radiation (7500 J/m2), IMIP (imipramine: 500 µM) alone or
immediately post-UVB irradiation, C2-C (C2-ceramide: 40 µM) or Di-C (Dihydroceramide: 40 µM) topically on the surface of shaved area. The mice were then
returned to their individual cages. After 4 hours, mice were euthanized in the CO2
tank and cervically dislocated. Skin tissue biopsy was taken from mouse skin
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using 5 mm disposable biopsy punch. Skin MVP was isolated following
procedures previously introduced in 3.2.1.

3.3.2 Mice blood plasma sample preparation
Immediately after mice were euthanized, blood was collected from heart in
heparin-coated tubes for plasma preparation. Blood in heparin-coated tubes was
spin at 2,000 x g for 20 minutes to remove blood cells, the upper clear layer was
then carefully pipetted into a new tube and measured for the plasma volume.
Once blood plasma was isolated, samples were followed by general MVP
isolation procedures previously introduced in 3.1.3.

3.4 Patient blood plasma sample preparation
Patients who were on a high dose of UVB phototherapy as their skin disease
treatment with greater than 20 times were enrolled in this IRB-approved study.
Blood was drawn before, two- and four-hours post-treatment in heparin-coated
tubes. Blood plasma MVP was isolated following the procedures as previously
described in 3.3.2.

29

3.5 Microvesicle particle measurement using Nanoparticle Tracking
Analysis
The concentration of MVPs was determined by using a NanoSight NS300
instrument (NanoSight Ltd, Malvern Instruments, Malvern, UK). Three 30-second
videos of each sample were recorded and analyzed with the Nanoparticle
Tracking Analysis (NTA) software version 3.0 to determine the concentration and
size of measured particles with corresponding standard error. The cell-derived
MVP concentration result was presented as total MVP number normalized to cell
number. Skin-isolated MVP concentration result was presented as total MVP
number normalized to skin biopsy tissue weight. Blister fluid MVP concentration
was calculated as total MVP number normalized to blister fluids volume. Blood
plasma MVP concentration result was presented as total MVP number
normalized to blood plasma volume.

3.6 Calcium-sensing receptor detection in cell by fluorescent microscopy
Cells were washed with PBS 3 times and fixed using 4% paraformaldehyde in
PBS for 10 min at room temperature then blocked by 1% extracellular depleted
FBS for 30 minutes, incubated in primary antibody anti-CaSR antibody at a ratio
of 1:100 and incubated for 1 h at room temperature, and incubated using Alexa
Fluor 488 conjugated secondary antibody at a ratio of 1:100 in the dark for 30
minutes. Images were taken and green fluorescent stained CaSR was observed
by fluorescent microscopy.
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3.7 Calcium-sensing receptor positive microvesicle particle detection using
Flow Cytometry
Each MVP sample was aliquoted into three microtubes to ensure each tube have
similar MVP number, MVP was blocked by 1% extracellular vesicles depleted
FBS for 30 minutes, incubated in primary antibody anti-CaSR antibody
conjugated with FITC (purchased from Novus Biologicals) at a ratio of 1:100 and
incubated for 1 h at room temperature. PBS was then added and sample was
proceeded with the measurement using a flow cytometer99.

3.8 Human cytokine detection in microvesicle particles
MVP isolated from treated HaCaT cell was re-suspended with 100 µl filtered PBS
and stored at -80 °C before assay.

3.8.1 Human cytokine 27-plex Assay
Cytokine and chemokine levels were measured by Bio-Plex ProTM Human
Cytokine 27-plex Assay Kit (purchased from Bio-Rad) following the kit protocol.
27 cytokines and chemokines were analyzed including FGF basic, Eotaxin, GCSF, GM-CSF, IFN-γ, IL-1β, IL-1ra, IL-2, IL-4, IL-5, IL-6, IL-7, IL- 8, IL-9, IL-10,
IL-12 (p70), IL-13, IL-15, IL-17, IP-10, MCP-1 (MCAF), MIP-1α, MIP-1β, PDGFBB, RANTES, TNF-α, and VEGF. Final results were presented as cytokine
concentration (pg/ml) normalized to total MVP number for analyzing.
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3.8.2 Enzyme-Linked Immunosorbent Assay
Human IL-8 ELISA Kit purchased from R&D systems was used to quantify the
concentration of IL-8 released from treated cells and expressed in HaCaTderived MVPs. The procedure was following the kit protocol. Samples were read
in a micro-plate reader and the IL-8 concentration was calculated using the
standard curve with a known concentration of IL-8 as reference. Final result
presented as IL-8 concentration (pg/ml) normalized to sample total protein level.

3.9 Acid sphingomyelinase enzymatic activity analysis
Treated HaCaT cell was trypsinized and protein was extracted. Acid
sphingomyelinase enzymatic activity was detected using the Acid
Sphingomyelinase Activity Colorimetric Assay Kit (purchased from Abcam). The
aSMase activity was determined by measuring a colorimetric product with
absorbance at 570 nm (A570) proportional to the enzymatic activity present.

3.10 Platelet-activating factor receptor agonistic lipids activity detection
The presence of PAF like lipids in the total lipid extract samples were assessed
by the ability of lipid extracts stimulated IL-8 release in PAF-R expressing KBP
cell via activating PAF-R, but not in PAFR-deficient KBM cells as previously
reported. Lipids were extracted either from UVB treated HaCaT cell lysate, total
cell medium at various time points after UVB treatment or HaCaT-derived MVP,
and MVP-depleted medium supernatant 2 hours post-UVB irradiation. Lipids
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were added to PAF-R over-expressed KBP cells. The percentage of PAF-R
activation in the target KBP cell was determined by the ratio of IL-8 release
stimulated by lipid treatment compared to 1 nM CPAF positive control treatment.
The higher PAF-R activation rate in KBP cells indicated the higher expression of
PAF like lipids in HaCaT cells and cell-derived MVPs.

3.11 Mice ear inflammation detection
For lipid extracts treatment, mice ear was treated with either VEH (vehicle: 20 μl
of acetone), TPA (100 nM made in vehicle), CON-MVP (untreated HaCaTderived MVP), or UVB-MVP (UVB-induced HaCaT MVP) lipids extracts (from
1011 particles re-suspended in 20 µl acetone). For imipramine treatment, mice
ear was treated with wither VEH (vehicle: 90%DMSO+10%EtOH), UVB (2500
J/m2), IMIP (imipramine: 500 µM) alone or immediately post-UVB irradiation.
Mice ear thickness was measured using PEACOCK dial thickness gauge before
and 4 hours post-treatment. Ear swelling resulted in thickness increases were
indicated as a surrogate marker for skin inflammation.

3.12 Mice immunosuppressive effects detection
Mice immunosuppressive effects were determined by CHS assay. Contact
hypersensitivity (CHS) is a simple in vivo assay of cell-mediated immune function
in which exposure of epidermal and dermal cells to exogenous haptens results in
a delayed-type hypersensitivity reaction that can be measured and quantified.
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The CHS study followed by the protocol previously reported (see Figure 6).
Briefly, day 0, mice were treated with either SHAM (no treatment), CPAF (250 ng
in 100 µl saline i.p. injection), and UVB (7500 J/m2) irradiated on a 2.5 cm x 2.5
cm back skin area which hair removed using clippers. Five days later, nonirradiated shoulder skin was treated with 50 µl of 0.5% DNFB in vehicle (1:4
acetone:olive oil). After 9 days post-DNFB treatment, mice ear thickness was
recorded, then ear was treated again with either 10 µl of 0.5% DNFB or vehicle
alone. Mice ear thickness was recorded again after 24 hours post-second DNFB
treatment. The DNFB induced immune reaction was determined by the ear
thickness changes between DNFB sanitized ear and vehicle-treated ear. The
decreased ear swelling level compared to SHAM group indicated suppressed
immune responses.
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Shave the back and exposed to UVB
5 days
Non-irradiated part of back
treated with 0.5% DNFB
9 days
Right ear:0.5% DNFB
Left ear: Vehicle
24 hrs
Ear thickness
measured using PEACOCK dial
thickness gauge
Δ=Right-Left

Figure 6. Timeline of CHS experimental design.

3.13 Statistical analysis
All statistical calculations were performed using GraphPad Prism 6. Statistical
significance was determined using two-tailed student t-test, multiple comparison
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was calculated using one-way or two-way ANOVA with post-hoc Holm-Sidak
method, with alpha=5%.
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Chapter 4. RESULTS
4.1 UVB radiation stimulates MVP release in keratinocyte cell lines.
To determine the effects of UVB on MVP release, three keratinocyte cell lines,
HaCaT, nTERT and primary keratinocytes were used. HaCaT cells treated with
3600 J/m2 UVB-induced MVP release as early as 2 hours post-treatment. At 4
hours, the released MVP level was significantly increased compared to untreated
cell-derived MVPs (Figure 7A). In Figure 7B, UVB-induced MVP release in a
dose-dependent manner and reached peak at the dose of 3600 J/m2. When UVB
dose increased to 5400 J/m2, the MVP release was attenuated, indicated that the
maximal effect of UVB on HaCaT cells is around 3600 J/m2 in this study.
Treatment of nTERT and primary keratinocytes with UVB and cultured for 4
hours exerted similar responses to HaCaT cells, further supports that UVB
irradiation stimulates skin keratinocytes to release a large number of MVPs.
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Figure 7. UVB-stimulated MVP release in keratinocyte cell lines. (A) time and (B) dose-dependent test on UVB-induced MVP release in HaCaT cell. (C)
nTERT and (D) primary keratinocytes were treated with 3600 J/m2 UVB. MVP
was collected 4 hours post-treatment. UVB increased MVP release in all HaCaT,
nTERT and primary keratinocytes at the dose of 3600 J/m2 and 4 hours posttreatment. The data depicted are mean ± SD MVP number normalized to cell
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number from at least three independent experiments. P<0.01 (**), P<0.001 (***)
denotes statistically significant differences from untreated cells.

4.2 CaSR expressed in MVP as a keratinocyte-selective marker.
MVP released from cells have different functions due to their carried specific
signaling molecules from different parent cells. Use of cell-specific markers to
define the origin of MVP is important, especially when evaluating heterogeneous
populations as in circulating MVP. General keratinocyte markers are either high
molecule weight proteins sized around 450 kDa, extracellular released antigens,
or cytoplasmic proteins100, 101, which are less likely to be folded into and
expressed on the surface of an MVP. In this study, we defined a membrane
protein that general expressed in epithelial cells, the calcium-sensing receptor
(CaSR).

In Figure 8, immunofluorescent staining of HaCaT and KBP with CaSR antibody
supported the expression of CaSR on keratinocytes. Murine skin fibroblast
showed a negative response in CaSR expression. Flow cytometry result of MVP
derived from HaCaT (CaSR-positive), fibroblast (CaSR-negative) and endothelial
cell (CaSR-negative) supported our findings that CaSR can be used to label
keratinocyte-derived MVP.
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A
HaCaT

KBP

Fibroblast

B
HaCaT

Fibroblast

Endothelial cell

Figure 8. CaSR used as a marker to label keratinocyte-derived MVP. (A) skin
cells were stained with Alex Fluro 488 conjugated CaSR antibody. Only
keratinocytes (HaCaT and KBP) expressed CaSR in membrane and cytoplasm.
Fibroblast did not express CaSR. (B) Detection of CaSR-positive MVPs by Flow
Cytometry. Only keratinocyte (HaCaT) derived MVP showed CaSR positive
MVPs, fibroblast and endothelial cell-released MVPs were CaSR-negative MVPs.
Black line: MVP only; Blue line: MVP stained with isotype control; Red line: MVP
stained with CaSR antibody.
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4.3 UVB promotes MVP production in skin tissue.
Human skin explants were donated by patients receiving abdominoplasty or
brachioplasty surgeries. Once the skin is removed, it was processed to treatment
immediately within hours. Skin tissue was exposed to UVB light, then collected 4
hours post-irradiation to isolate MVPs. Figure 9A showed that UVB accumulated
MVP production in skin tissue.

Previously we have reported that UVB treatment resulted in increased MVP
concentration in skin blister fluid72. Once blister formed, the blister fluid separates
the epidermal and the dermal layer (see Figure 5). However, the origin of UVBinduced blister fluid MVP is unclear. We used the same model of human skin
blisters found similar result on UVB-induced MVP release (figure 9B) and tested
whether they were released from the skin epidermis. The flow cytometry result
(figure 9C) showed increased CaSR-positive MVP existed in blister fluids after
UVB treatment, which correlated with total blister fluid MVP and increased skin
tissue MVP, indicates that they were released from keratinocytes in the
epidermis into the blister fluids.
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Figure 9. UVB-induced MVP release in human skin explants. (A) Human skin
explants were treated with 3600 J/m2 UVB, after 4 hours, MVP concentration was
detected in skin biopsied tissue. (B) The blister was formed in human skin
explants by a negative pressure pump. After blister formed, the surface of the
blister was exposed to UVB at 3600J/m2. MVP was isolated from blister fluid 4
hours post-irradiation. UVB increased MVP concentration in both skin tissue and
blister fluid. (C) Flow cytometry results of CaSR expression in human blister fluid
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MVPs. Red line: CaSR staining, blue line: isotype control staining. The data
depicted are mean ± SD MVP number normalized to tissue weight or blister fluid
volume from at least three independent experiments. P<0.05 (*) denotes
statistically significant differences from untreated skin samples.

Not only in human skin, we also detected in vivo MVP production in mice skin.
WT mice were exposed to UVB on shaved back skin, tissue biopsy was collected
after 4 hours post-irradiation. Figure 10A showed that 5000 J/m2 UVB-induced
MVP production in mice skin tissue in a time-dependent manner. MVP
concentration at 8 hours was similar to the result at 4 hours, and at 24 hours the
MVP concentration was gradually returned back to normal level, indicate the
maximal effect of UVB-induced skin MVP production occurs around 4 to 8 hours
post-irradiation. After 8 hours, skin MVP was either degraded or uptaken by other
cells, thus the skin MVP concentration gradually decreases.

UVB-induced MVP production is also dose-dependent (Figure 10B). UVB
stimulated MVP production starting at the dose of 2500 J/m2. The dose of 7500
J/m2 UVB only exerted a minor increase in MVP concentration compared to 5000
J/m2 indicates that 7500 J/m2 may reach the peak dose.
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Figure 10. UVB exposure increased MVP concentration in mice skin tissue.
(A) time- and (B) dose-dependent test on UVB stimulated MVP production in
mice skin tissue. UVB-induced MVP release is in a dose- and time-dependent
manner. Skin MVP release returned close to normal level after 24 hours and
reached the peak around 4 to 8 hours. 2500 J/m2 UVB started to significantly
increases MVP release in the skin. 5000 J/m2 and 7500 J/m2 UVB seems
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reached the peak dose. The data depicted are mean ± SD MVP number
normalized to biopsied tissue weight from at least three independent
experiments. P<0.05 (*), P<0.01 (**), P<0.001 (***) denotes statistically
significant differences from untreated mice.

4.4 Keratinocyte-derived MVP can travel systematically following UVB
irradiation.
The important role of MVP in cellular communication is due to its ability to
transport signals and travel to distanced cells. The MVP released to blister fluid
from the epidermis indicated that keratinocyte MVP could travel systematically.
We investigated increased MVP concentration in the blood plasma of UVB
treated mice (Figure 11). Blood plasma MVP concentration changes after various
times post-UVB irradiation was similar to what have found in skin MVP which
peak at 4-8 hours and decreased back to normal after 24 hours (Figure 11A).
Blood plasma MVP responded to UVB showed a slighter effect compared to skin
MVP. Increased blood plasma MVP concentration initiated at the dose of 5000
J/m2 and significantly induced at the dose of 7500 J/m2, showed a delayed
response to UVB compared to skin MVP (Figure 11B). Figure 11C showed that
the presence of CaSR-positive MVPs in blood plasma correlated with the UVB
enhanced total blood plasma MVP (Figure 11B) and skin MVP concentration
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(Figure 10B), provides evidence that keratinocyte released MVP travels into

circulation following UVB treatment in a dose-dependent manner.
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Figure 11. UVB increased keratinocyte-derived MVP in mice blood plasma.
(A) time- and (B) dose-dependent test on UVB-induced MVP release in mice
blood plasma. UVB increased total MVP concentration in mice blood plasma in a
time- and dose-dependent manner. The maximal effect occurred at a dose of
7500 J/m2 and 4 hours post-UVB treatment. (C) Blood plasma MVP were stained
with the keratinocyte-selective marker CaSR. Red line: CaSR staining, blue line:
isotype control staining. The increased CaSR-positive MVP was correlated with
increased total MVP expression in blood plasma and skin tissue. The data
depicted are mean ± SD MVP number normalized to blood plasma volume from
at least three independent experiments. P<0.05 (*), P<0.01 (**), P<0.001 (***)
denotes statistically significant differences from untreated mice.

More interestingly, keratinocyte-derived MVP has been found in human blood.
Patients with skin disorders and treated with multi-times of phototherapy were
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selected. Blood was drawn before, 2 hours post- and 4 hours post-whole body
UVB phototherapy. The blood plasma MVP concentration significantly increased
at 4 hours post-UVB treatment (Figure 12A, detailed inflammation sees Table 1).
The proportion of CaSR-positive MVP in total blood plasma MVP was elevated
after 4 hours post-UVB treatment (Figure 12B), which correlated with enhanced
total blood plasma MVP, indicating they were produced in keratinocyte and
transferred into the blood after 4 hours post-UVB irradiation.

A

*

15

10

9

p a r t ic le s / c e ll)

20

(1 0

5

r
H
4

H
2

0

H

r

0

r

B lo o d P la s m a M V P C o n c .

H u m a n B lo o d M V P

B
0h

2h

4.56%

8.15%

48

4h

36.05%

Figure 12. UVB phototherapy increased keratinocyte-derived MVP in human
blood plasma. (A) Blood was drawn from human patients who received multiple
phototherapies before, 2 hours post- and 4 hours post-UVB therapy (N=4).
Similar to cellular result, UVB significantly induced MVP release in blood at 4
hours post-irradiation. (B) Flow cytometry results of CaSR expression in MVPs
isolated from patient blood plasma. Red line: CaSR staining, blue line: isotype
control staining. The increased percentage of CaSR-positive MVP in total blood
plasma MVP indicated that they were travel from skin keratinocyte. The data
depicted are mean ± SD MVP number normalized to blood plasma volume.
P<0.05 (*) denotes statistically significant differences from pre-UVB therapy
induced blood plasma MVP.

Table 1. Blood Plasma MVP measurement from patients who received UVB
phototherapy.
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4.5 UVB-induced MVP release requires PAF-R.
PAF-R activation plays an important role in UVB induced inflammatory and
immunosuppressive effects33, 37. It has been found that activation of PAF without
UVB irradiation can stimulate MVP release in HaCaT cells 94. We further
confirmed this finding on three keratinocyte cell lines, HaCaT, nTERT and
primary keratinocytes that PAF-R activation by 100 nM CPAF treatment-induced
MVP release in keratinocytes (Figure 13).

A

B

C

Figure 13. PAF-R activation by CPAF stimulated release of MVP in
keratinocytes. CPAF treatment-induced MVP release from (A) HaCaT, (B)
nTERT, and (C) primary keratinocytes. The data depicted are mean ± SD MVP
number normalized to cell number from at least three independent experiments.
P<0.05 (*) denotes statistically significant differences from vehicle-treated cells.
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KBP was generated PAF-R overexpressed KB keratinocyte where KBM
remained PAF-R deficient. This cell model was used to determine PAF-R
dependency on UVB stimulated MVP release. Treatment of KBP cell with 100 nM
CPAF and 3600 J/m2 UVB significantly increased MVP release. KBM cell did not
respond to UVB and CPAF on MVP release due to a lacking PAF-R. The
inhibitory effect of PAF-R deficiency suggests that PAF-R is required for UVBinduced MVP release in keratinocyte. The phorbol diester, TPA (phorbol 12myristate 13-acetate, also named as PMA) activates PKC in a PAF-R
independent pathway to produce similar effects as PAF-R activation such as
cytokine releases102, 103. Therefore, TPA stimulated KBM cell independent of
PAF-R and used as a PAF-R independent positive control.
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Figure 14. UVB-induced MVP release is PAF-R dependent. PAF-R positive
KBP cell and PAF-R negative KBM cell were treated with CPAF and UVB. UVB51

and CPAF-induced MVP release was only present in KBP but not in KBM cells
indicated the importance of PAF-R expression on MVP release in keratinocyte.
The data depicted are mean ± SD MVP number normalized to cell number from
at least three independent experiments. P<0.05 (*), P<0.01 (**), P<0.001 (***)
denotes statistically significant differences from untreated or vehicle-treated cells,
P<0.05 (^) and P<0.001 (^^^) represents significant differences between treated
KBP and KBM cells.

PAF-R KO mice were generated by knock-out of ptafr gene. In WT mice, UVB
induced MVP production in both skin tissue and blood plasma. When treated
PAF-KO mice with 7500 J/m2 UVB light, both skin MVP and blood plasma MVP
concentration did not respond to UVB treatment (Figure 15) confirmed that UVB
activated PAF-R contributes to MVP release in keratinocyte. CPAF had no effect
on PAF-KO mice where TPA could sufficiently activate MVP release in a PAF-Rindependent manner, confirming the PAF-R deficiency in PAF-KO mice. The
blockage of UVB-induced skin MVP release contributed to non-affected blood
plasma MVP concentration, also supports that enhanced blood plasma MVP is
released from the skin keratinocyte.
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B

A

Figure 15. MVP production inhibited in mice lacking PAF-R. (A) UVB
triggered MVP production in mice skin was inhibited in PAF-R KO mice lacking
PAF-R. (B) PAF-R KO mice blood plasma MVP did not respond to UVB
treatment due to the PAF-R deficiency blocked keratinocyte MVP release from
the skin. The data depicted are mean ± SD MVP number normalized to biopsied
skin tissue weight and blood plasma volume from at least three independent
experiments. P<0.01 (**) denotes statistically significant differences from
untreated mice. N.S. represents there is no significant difference from untreated
mice.
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4.6 PAF-R activation regulates aSMase activity.
PAF-R activation is able to regulate aSMase translocate from the lysosome to
the plasma membrane resulting in enhanced ceramide level95, 104. Ceramide is
the key lipid mediator regulating MVP release in the lipid-associated pathway105.
To examine whether UVB-induced PAF-R activation and aSMase were involved
in MVP release, we tested the enzymatic activity of aSMase in CPAF and UVB
treated HaCaT cell. The result in Figure 16A showed enhanced aSMase activity
induced by CPAF and UVB treatment. The baseline level of aSMase activity
varies in HaCaT, KBP, and KBM cell (Figure 16B). PAF-R overexpressed KBP
cell had the highest basal aSMase activity compared to HaCaT cell. KBM cell
lacking PAF-R showed minor basal aSMase activity, indicates that aSMase
activity correlates with PAF-R expression level.
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Figure 16. PAF-R activation regulates aSMase activity. (A) HaCaT cell treated
with 100 nM CPAF and 3600 J/m2 UVB enhanced cellular aSMase activity. The
data depicted are mean ± SD aSMase enzymatic activity fold change compared
to untreated cells from at least three independent experiments. P<0.05 (*),
P<0.001 (***) denotes statistically significant differences from untreated cells. (B)
KBP cell exerted the highest baseline aSMase activity indicates that aSMase
activity correlates with PAF-R expression. The data depicted are mean ± SD
aSMase enzymatic activity normalized to cellular protein level from at least three
independent experiments. P<0.001 (***) denotes statistically significant
differences from HaCaT cells.
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4.7 UVB-induced MVP release is aSMase dependent.
UVB activated PAF-R activation is required for keratinocyte to release MVP.
PAF-R activation is able to regulate aSMase activity which may contribute to
MVP release. Inhibition of aSMase by imipramine sufficiently blocked UVBinduced MVP release in HaCaT cells (Figure 17). Not only in cells, the topical
application of imipramine immediately after UVB irradiation also blocked UVB
stimulated MVP production in human skin explants (Figure 18) and mice skin
(Figure 19). Knock-out of the smpd1 gene resulted in aSMase deficiency in
aSMase KO mice did not respond to UVB treatment in skin MVP production
(Figure 20A) thus inhibited the keratinocyte-derived MVP expression in blood
(Figure 20B). Deficiency in aSMase enzymatic activity blocks ceramide
production which blocks MVP release. Topical treatment of a ceramide analog,
C2-ceramide, restored the MVP release in aSMase KO mice skin and blood. The
inactive formed dihydroceramide showed no effect confirmed that aSMaseinduced ceramide production contributes to the keratinocyte MVP release
pathway. These findings provide numerous lines of evidence that aSMase acts
as a downstream effector for PAF-R activation in the UVB-induced MVP release
pathway.
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Figure 17. UVB-induced HaCaT MVP production blocked by aSMase
inhibitor. HaCaT cell treated with 50 μM imipramine, an aSMase inhibitor,
immediately after UVB exposure at the dose of 3600 J/m2 sufficiently blocked
UVB stimulated MVP release. The data depicted are mean ± SD MVP fold
change compared to untreated cells from at least three independent
experiments. P<0.001 (***) denotes statistically significant differences from
untreated cells. P<0.001 (^^^) denotes statistically significant differences from
UVB-treated cells.
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Figure 18. Inhibitor of aSMase blocked UVB-induced MVP production in
human skin explants. Human skin explants tissue was exposed to 3600 J/m2
UVB. Treatment of aSMase inhibitor, 50 µM imipramine was added immediately
after UVB irradiated on the surface of the skin. Imipramine blocked UVB-induced
MVP production in skin tissue. The data depicted are mean ± SD MVP fold
change compared to untreated skin tissue from at least three independent
experiments. P<0.001 (***) denotes statistically significant differences from
untreated skin tissue. P<0.001 (^^^) denotes statistically significant differences
from UVB-treated skin tissue.
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Figure 19. Inhibitor of aSMase blocked UVB-induced MVP production in WT
mice. WT mice were treated with 7500 J/m2 UVB on the shaved back skin. Both
UVB and topical C2-ceramide treatment-induced MVP production in mice skin.
Inhibition of aSMase by imipramine blocked UVB-induced MVP release in WT
mice skin. The data depicted are mean ± SD MVP fold change compared to
untreated mice from at least three independent experiments. P<0.05 (*), P<0.001
(***) denotes statistically significant differences from untreated or vehicle-treated
mice. P<0.001 (^^^) denotes statistically significant differences from UVB-treated
mice.
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Figure 20. UVB-induced keratinocyte MVP in both skin and blood inhibited
in mice lacking aSMase. (A) Treatment of 7500 J/m2 UVB had no effect on MVP
release in aSMase KO mice skin. The topical treatment of C2-ceramide retained
its ability to produce MVP in aSMase KO mice skin. (B) UVB did not affect blood
plasma MVP level in aSMase KO mice. Topical C2-ceramide treated skin
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increased blood plasma MVP concentration in aSMase KO mice which correlated
with increased skin MVP concentration. The blocked UVB-induced blood plasma
MVP also correlated with inhibited skin MVP production in aSMase KO mice. The
data depicted are mean ± SD MVP fold change compared to untreated mice from
at least three independent experiments. P<0.01 (**) denotes statistically
significant differences from vehicle-treated mice.

4.8 Keratinocyte-derived MVP carries cytokines.
Several studies have reported that cytokines transferred by MVPs regulate target
cell inflammatory and immune responses74, 75, 77. Given that UVB stimulates PAFR activation and cytokine production, we tested 27 cytokines in MVP derived
from HaCaT cell treated with 100 nM CPAF, or 3600 J/m2 UVB for 4 hours using
the Bio-Plex Pro™ Human Cytokine 27-plex Assay. In contrast to what we have
predicted, the majority of pro-inflammatory and immune regulatory cytokines and
chemokines in UVB-induced MVP were extremely low (see Table 2 for details).
Of note, levels of IL-1 receptor antagonist (IL-1ra), a cytokine with antiinflammatory properties106, was elevated in UVB-induced HaCaT MVP. The
cytokine expression implied a potential protective anti-inflammatory property of
UVB-induced MVP. CPAF activates keratinocyte PAF-R, PAF-R activation is
involved in UVB induced immune responses. Even though most of the cytokines
expressed in keratinocyte-derived MVP were not regulated by CPAF treatment,
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their expression regulated by CPAF different from UVB regulated cytokine
expression. This finding suggests that different stimuli can alter MVP contents in
keratinocyte.

To verify the accuracy of cytokine expression in HaCaT MVP. Detection of IL-8
by ELISA was conducted on CPAF and UVB treated HaCaT and KBP MVP
(Figure 22). CPAF upregulated IL-8 expression in keratinocyte-derived MVP
where UVB had the opposite effect which had a similar tendency to the human
27 cytokine assay.
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Figure 21. Cytokine and chemokine expression in UVB and CPAF treated
HaCaT MVP. MVPs were prepared 4 hours after 100 nM CPAF and 3600 J/m2
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UVB treatment. 27 cytokines and chemokines were detected in HaCaT-derived
MVPs. Most of them showed extremely low expression but IL-1ra was
significantly increased in UVB-induced HaCaT MVPs. Result was calculated by
cytokine concentration normalized to MVP number, fold change was calculated
by UVB and CPAF-induced MVPs normalized to untreated MVPs. Cytokine
expression in untreated HaCaT cell-derived MVP was set as a baseline, showed
as dotted line: - - - - -.
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Table 2. Cytokine and chemokine expression in UVB and CPAF treated
HaCaT MVP. Data were presented as mean (+/-SD).
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A

B

Figure 22. IL-8 expression in keratinocyte-derived MVP after UVB or CPAF
treatment. (A) HaCaT and (B) KBP cells were treated with CPAF or UVB for 4
hours to generate MVP. IL-8 expression in cell-derived MVPs was detected by
ELISA. CPAF-induced HaCaT MVP and KBP MVP had increased expression
and UVB treated cell-derived MVP had decreased IL-8 expression compared to
untreated cell-derived MVPs. The data depicted are mean ± SD IL-8 level
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normalized to protein level from at least three independent experiments. P<0.001
(***) denotes statistically significant differences from untreated cells.

4.9 Keratinocyte-derived MVP carries PAF-R agonistic lipids.
PAF signals can be transferred from keratinocytes to mast cells involved in UVB
mediated immunosuppression107. The reduced cytokine expression in UVB
stimulated HaCaT MVPs implied that inflammatory lipids rather than cytokines
were responsible for MVP to transfer signals from keratinocyte. Besides PAF,
there are many PAF like ox-GPCs that can also activate PAF-R that were
determined as PAF-R agonistic lipids40. The structure of many PAF-R agonistic
lipids was still remained uncharacterized. Therefore, instead of directly
characterize the presence of PAF lipid analogs in MVPs, we analyzed the ability
of total PAF lipids to activate PAF-R activation in target cells, which considered
the PAF-R agonistic activity (see Figure 23A for procedure).

Treatment of HaCaT cell with UVB promotes PAF like lipid formation. After time
passed post-irradiation, the ability of lipid extracts from cell lysate to activates
PAF-R decreased while extracellular released PAF-like lipids showed increased
responses on PAF-R activation (Figure 23B), indicated that PAF like lipids were
released from keratinocytes after UVB treatment. The extracellular PAF lipids
induced PAF-R response maximized at 2 hours post-UVB irradiation. To further
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analyze whether the extracellular released PAF like lipids were loaded in the
keratinocyte-derived MVP, lipids extracted from HaCaT MVP and MVP depleted
medium was generated. Result in Figure 23C showed that lipids extracted from
UVB-induced HaCaT MVP excreted strong PAF-R activation response almost
similar to 1 nM CPAF induced PAF-R activation (>80%). Lipids extracted from
UVB-induced MVP depleted medium and untreated HaCaT-derived MVP only
had minor PAF-R agonistic responses. These findings indicate that with UVB
treatment, PAF-R lipids are loaded into MVP and maintained their activity stably
in the MVP. PAF like lipids traveled with keratinocyte derived-MVP could activate
PAF-R in target cells, suggests a potential mechanism of systematic PAF
signaling transferences.
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Figure 23. UVB-induced HaCaT MVP carried PAF like lipids. (A) Schematic
diagram of the PAF-R agonistic activity procedure. Lipids extracted from HaCaT
cell lysate, culture medium, MVP isolated from medium and MVP depleted
medium were collected and added to KBP cell for PAF-R agonistic activity
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analysis. IL-8 release was used as an indicator of PAF-R activation in KBP cell.
The lipid treatment-induced response was compared to 1 nM CPAF treatmentinduced positive response and final result presented as % of CPAF induced
positive PAF-R response. (B) After 3600 J/m2 UVB treatment, the cellular PAF-R
agonistic lipids were gradually decreased where the extracellular released lipids
were gradually increased and reached a peak level at 2 hours post-treatment. (C)
MVP was separated from UVB treated HaCaT culture supernatant 2 hours posttreatment. Lipids extracted from HaCaT MVP and MVP depleted supernatant
were added to KBP cell for PAF-R agonistic activity test. Most of the PAF-R
activity was induced by lipids that exist in MVP, not from MVP depleted
supernatant, indicates that UVB induced PAF lipids are mainly presented in
HaCaT MVPs. The data depicted are mean ± SD % of CPAF induced PAF-R
agonistic response from at least three independent experiments.

PAF is a potent proinflammatory mediator contributes to a wide range of
inflammatory processes. It has shown to have important roles in platelet and
neutrophil aggregation, vascular permeability, leukocyte adhesion and
migration108. To further investigates the bioactivity of MVP carried PAF like lipids,
we added the lipid extracts from HaCaT MVP after UVB treatment directly onto
mice ears. At 4 hours post-treatment, UVB-induced MVP lipids resulted in ear
swelling in WT mice only, not in PAF-R KO mice (Figure 24), indicates that the
inflammatory response is PAF-R dependent. This inflammatory response
69

supports that UVB induced HaCaT MVP carry pro-inflammatory PAF like lipids,
which contribute to skin inflammation via PAF-R activation.
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Figure 24. Lipids extracted from UVB-MVP induced ear inflammation in a
PAF-R dependent manner. Lipids extracted from UVB-induced HaCaT MVP
caused increased ear thickness changes due to ear swelling. Untreated HaCaT
MVP lipids had no inflammatory effect. This inflammatory response blocked in
PAF-R KO mice indicated the PAF-R dependency on UVB induced inflammation.
TPA stimulates skin independent of PAF-R, used as PAF-R independent positive
control in PAFR-KO mice. The data depicted are mean ± SD ear thickness
changes from at least three independent experiments. P<0.05 (*), P<0.01 (**)
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denotes statistically significant differences from vehicle-treated mice. P<0.05 (^)
denotes statistically significant differences between WT mice and PAF-R KO
mice.

4.10 PAF-R can be carried and transferred by keratinocyte-derived MVP.
Despite the findings that keratinocyte derived MVP carries cytokines and
bioactive lipids, and the lipid extracts can cause skin inflammation, whether UVB
can directly transfer the inner content to initiate physiological functions need
further investigation. We used the KB model to test whether the membrane
protein PAF-R can be directly transferred by MVP from KBP cell to KBM cell
(Figure 25). KBM cell lacking PAF-R could not respond to CPAF and UVB
treatment. After it cultured with KBP-derived MVPs for 24 hours, treatment with
CPAF showed increased IL-8 release, indicates the presence of a small amount
PAF-R in KBM after MVP treatment. UVB-induced KBP MVP showed slightly
higher IL-8 response compared to untreated KBP MVPs might be associated with
UVB mediated PAF-R activation in KBP cells. The transference of PAF-R by
MVP proved that keratinocyte-derived MVP can transfer its inner content
molecules from parental cells into target cells.
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Figure 25. MVP transferred PAF-R in KB cell. (A) Experimental design of KBPderived MVP co-culture with KBM cell. KBP cells treated with or without UVB
released MVPs were collected and added to PAF-R negative KBM cells. After co-
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cultured for 24 hours, KBM cells were treated with CPAF to test whether PAF-R
has been transferred from KBP to KBM via MVP. (B) KBM did not respond to
CPAF treatment due to lacking PAF-R. After treatment of KBP MVP, KBM
responded slightly to CPAF resulted in increased IL-8 release indicates the ability
of MVP to transfer PAF-R signal. The data depicted are mean ± SD IL-8 release
from at least three independent experiments. P<0.001 (***) denotes statistically
significant differences from vehicle-treated cells. P<0.05 (^), P<0.001 (^^^)
denotes statistically significant differences from vehicle-treated cells with MVP
treatment.

4.11 Inhibition of aSMase blocks UVB-induced inflammation and
immunosuppression.
Given our findings that UVB-induced keratinocyte MVPs carry PAF-R agonistic
lipids and are able to stably transfer to target cells, target on MVP release could
provide potential protective effects on UVB induced inflammatory and systematic
immunosuppressive effects via blockage of PAF signaling transference. To
assess that, we tested whether aSMase inhibition blocked MVP release had any
effects on UVB induced acute inflammatory response in mice ear and
immunosuppressive effects via CHS study.
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Mice ears were exposed to 2500 J/m2 UVB and then immediately treated with
imipramine topically on the skin. As shown in Figure 26, UVB irradiation-induced
significant skin thickness increases at 2 hours post-irradiation. Topical
imipramine treatment effectively blocked this UVB induced inflammatory
response consistent with the inhibitory effect on skin MVP release, suggests that
target on MVP release could regulate UVB-associated inflammatory process.

In CHS studies, WT mice, PAF-R KO mice and aSMase KO mice were treated
with UVB on shaved back skin and later sanitized with DNFB on non-irradiated
skin area. Re-exposure to DNFB on mice ear initiated a rapid local inflammatory
response peak at 24 hours resulted in ear swelling (increased ear thickness) in
mice. As showed in Figure 27, both UVB and CPAF treatment impaired the
DNFB elicited inflammatory response in WT mice resulted in reduced ear
thickness changes suggests the PAF-R activation mediated immunosuppression.
The inhibition of UVB- and CPAF-induced CHS reaction in PAF-R KO mice
confirmed the PAF-R dependency on UVB induced immunosuppression.
Interestingly, aSMase KO mice only responded to CPAF, not UVB. The
suppression of UVB on DNFB elicited inflammatory response blocked in aSMase
KO mice resulted in unchanged ear thickness compared to untreated mice.
Exogenous CPAF injection bypassed the inhibition of MVP transferred PAF
signals by aSMase deficiency, and stimulates mast cells to initiate
immunosuppression, thus maintained its suppressive effects on aSMase KO
mice. These results in aSMase KO mice suggest that PAF signals transferred by
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keratinocyte-derived MVP mediates UVB-induced systematic
immunosuppression.
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Figure 26. UVB-induced skin inflammation blocked by aSMase inhibitor.
Mice exposed to 2500 J/m2 UVB light on ears resulted in ear swelling caused
thickened skin. Topical treatment of imipramine blocked the UVB-induced ear
thickness changes. The data depicted are mean ± SD ear thickness changes
from at least 5 mice. P<0.05 (*) denotes statistically significant differences from
vehicle-treated mice. P<0.05 (^) denotes statistically significant differences from
UVB-treated mice.
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Figure 27. UVB-induced CHS response inhibited in mice lacking aSMase
and PAF-R. WT mice, PAF-R KO mice and aSMase KO mice were treated with
either no treatment, CPAF (250 ng I.P. injection) or 7500 J/m2 UVB to test CHS
reaction. CPAF-induced immunosuppression in aSMase KO mice similar to WT
mice but blocked in PAF-R KO mice. UVB-induced immunosuppression blocked
by both PAF-R deficiency and aSMase knock-out suggest that aSMase and PAFR dependent UVB-induced MVP release may be involved in the delayed
systematic immunosuppression. The data depicted are mean ± SD ear thickness
changes from at least three independent experiments with more than three mice
in each experiment. P<0.001 (***) denotes statistically significant differences from
untreated mice.
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Chapter 5. DISCUSSION
UVB and PAF-R activation induces a large amount of keratinocyte MVP release
that has been previously reported with an unknown releasing mechanism and of
unclear role in UVB effects94. PAF-R activation induced aSMase activity found to
mediate thermal burn injury-induced keratinocyte MVP release97. To assess
whether UVB-induced keratinocyte MVP share the same releasing mechanism,
we analyzed PAF-R and aSMase dependency on MVP release with UVB
treatment in three keratinocyte cell lines in vitro, in human skin explants ex vivo,
and mice skin and blood in vivo.

5.1 UVB irradiation on mice showed a delayed but similar effect on MVP
release compared to cell and human skin.
Both UVB radiation and CPAF treatments-induced MVP release in all three
keratinocytes (Figure 7 and Figure 13). UVB stimulates HaCaT cells to release
MVP in a dose- and time- dependent manner (Figure 7). The maximal effect
occurs at a dose of 3600 J/m2 after 4 to 8 hours post-UVB radiation. A similar
release pattern also found in mice skin (Figure 10) and mice blood (Figure 11).
However, the UVB dose that affecting MVP release in mice is much larger
compared to cell treatment and human skin treatment. Previously studies
showed that different species respond differently to UVB. The vascular
responses to UV injury in rats differ from other animals including guinea-pig and
rabbit. Mice had slighter erythema and reduced vascular permeability responses.

77

In addition, leukocytosis is delayed in onset and comparatively slight in degree109,
110

. Therefore, we used the stronger functional dose of UVB, 7500 J/m2 on mice

experiments which is much higher compared to the dose of 3600 J/m2 on cell
and human treatment.

5.2 Enhanced presence of CaSR-positive keratinocyte-derived MVPs
detected in blood plasma after UVB treatment.
The findings of increased MVP in human blood (Figure 11) and mice blood
(Figure 12) with skin UVB treatment is consistent with increased MVP production
in the skin (Figure 10). MVPs found in circulation are released from various cells.
Due to its perspective functions related to the parental cells, defining the origin of
MVP, especially in the circulating MVP is important. Cell-specific markers were
used to target MVPs in patient blood such as CD62P target platelet-derived
MVP, CD45 target leukocyte-derived MVP, CD235a target red blood cell-derived
MVP, CD62E and CD31 target endothelial cell-derived MVP99,111. To further
identify whether the increased mice and human blood MVP is from the skin
keratinocyte in our study, we needed to discover a specific marker to target
keratinocyte MVP. We found a membrane protein, CaSR which is expressed in
keratinocyte and not presented in skin fibroblast (Figure 8A). CaSR positively
stained HaCaT cell-derived MVP by Flow Cytometry where fibroblast and
endothelial cell-derived MVP are negative to CaSR staining (Figure 8B).
Increased CaSR-positive MVP in blood consistent with enhanced total blood
plasma MVP in patient blood (Figure 12) and mice blood (Figure 11B and 11C)
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indicates that increased blood plasma MVPs are CaSR-positive. The increased
blood plasma MVP consistent with enhanced skin MVP production in WT mice
(Figure 11C and Figure 10B), PAF-R KO mice (Figure 15), and aSMase KO mice
(Figure 19) suggests that keratinocyte-derived MVP produced in the skin can
travel to blood to interact with distal cells after UVB exposure. However, the most
abundant expression of CaSR is on the keratinocyte cytoplasm rather than
plasma membrane112, it is not guaranteed that all MVPs will express CaSR.
CaSR-positive MVP can only indicate the relative presence of keratinocytederived MVP, not the quantity. To fully identify the proportion of keratinocyte
released MVP in circulating MVP, a better keratinocyte-specific marker needs to
be investigated.

5.3 Keratinocyte-derived MVPs carry anti-inflammatory cytokine IL-1ra and
pro-inflammatory PAF lipids.
UVB induced PAF-R activation stimulates keratinocytes to release abundant proinflammatory cytokines such as IL-8 and TNF-α. MVP is known to transfer
cytokines involved in numerous physiologic processes. In contrast to what we
expected that MVP can carry UVB-induced pro-inflammatory cytokines, both
cytokine assay and ELISA result (Figure 21 and 22) demonstrated that UVB
irradiation results in the formation of keratinocyte-derived MVP carrying few proinflammatory cytokines. The only enhanced cytokine is IL-1 receptor antagonist,
IL-1ra. IL-1ra competitively binds to the IL-1 receptor which produces no
activation but blocks IL-1 interaction. The use of neutralizing anti-IL-1ra
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antibodies has demonstrated that endogenous IL-1ra is an important natural antiinflammatory protein in arthritis, colitis, and granulomatous pulmonary disease106.
Hirao et al. demonstrated that IL-1 alpha activity dominates in normal human
skin. After human skin exposed to UV, the ratio of IL-1ra to IL-1 alpha increased
from 8 to 100, that IL-1ra dominantly binds to IL-1 receptor and inhibits the
biological function of IL-1113. Furthermore, a UV dose of 2 MED was shown to
dramatically upregulate IL-1ra in the stratum corneum of human volunteers,
leading to the suggestion that IL-1ra inhibits excessive inflammation and may
account for some of the UVB-induced immunosuppression113-115.

Considering that MVP directly generated in the plasma membrane which
enriched with lipids, we assessed the ability of MVPs to carry and transfer the
bioactive PAF lipids and the membrane protein PAF-R in keratinocyte-derived
MVP. We found that PAF lipids were transferred from the cell into MVP at 2
hours post-UVB treatment (Figure 22). PAF is rapidly cleared from the
circulation and has a limited half-life (3–13 minutes) due to its degradation by
PAF-AH116. While the cellular PAF degraded, PAF transferred into HaCaTderived MVP retained its bioactivity and thus this novel transport mechanism
could protectively transfer metabolically labile PAF lipids to other cells where
MVP travel. The treatment of lipids extracted from UVB induced MVPs only
actively induced inflammation in WT mice, but not PAF-R mice (Figure 24),
confirmed that they are PAF like lipids that function through PAF-R. Even though
we provided evidence that keratinocyte-derived MVP is able to transfer content
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molecules such as membrane proteins from cell to cell (Figure 25), future
experiments of directly adding MVP, rather than lipid extracted from MVP need to
be done to fully characterize keratinocyte MVP functions in skin inflammation.

5.4 Target on MVP release could regulate UVB-induced inflammation and
systematic immunosuppression.
PAF-R and aSMase dependency on MVP release was fully analyzed using PAFR deficient keratinocyte (Figure 14), aSMase inhibitor (Figure 17-19), and the
knock-out mice models (Figure 15 and Figure 20). The induced aSMase activity
by CPAF treatment (Figure 16A) indicates that aSMase activity is the
downstream effector of PAF-R activation, which provide a potential release
pathway of UVB-induced keratinocyte MVP involved in PAF-R activation and its
activated aSMase enzyme activity. The lysosomal enzyme aSMase can be
transferred to plasma membrane resulted in increased ceramide content on the
membrane. Ceramide has been shown to regulate MVP release in several
studies. Future experiments of regulated ceramide contents in keratinocyte with
UVB irradiation and CPAF induced PAF-R activation could help to further
supports the PAF-R – aSMase pathway for UVB-induced MVP release.
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Inhibition of UVB induced inflammatory response (Figure 26) and CHS reaction
(Figure 27) in aSMase KO mice is consistent with the inhibition of MVP release
by aSMase deficiency (Figure 20) indicates that keratinocyte-derived MVP
release is associated with UVB induced inflammation and immunosuppression.
Previously we reported that with UVB exposure, PAF-R on mast cell has been
activated to mediate mast cell migration and cytokine release resulted in
systematic immunosuppression107. Though UVB cannot penetrate the dermis to
directly activate mast cells, and keratinocyte produced PAF will be quickly
degraded and unlikely to directly transfer to the distal environment. PAF signals
transferred by keratinocyte-derived MVP might be the key for keratinocyte to
interact with mast cells. Keratinocyte-derived MVP carries PAF like lipids which
can be stably transferred to mast cells to activate its PAF-R. PAF-R activation in
mast cell triggers the release of histamine and PGs which further stimulate mast
cell migration and interaction with T cells to mediate immune response. Inhibition
of keratinocyte-derived MVP by PAF-R and aSMase inhibitor could contribute to
blockage of PAF signaling transferases and mast cell PAF-R activation, which
involved in UVB induced inflammation and systematic immunosuppression.
Future studies of keratinocyte MVP inhibition regulated mast cell activity and
even further T cell interactions needed to fully reveal the role of MVP on UVB
induced immunosuppression.
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Chapter 6. GENERAL CONCLUSIONS
In this study, we found that UVB stimulates keratinocyte to release MVPs via a
PAF-R – aSMase dependent pathway. Blockage of PAF-R activation and
aSMase activity can sufficiently inhibit UVB-induced keratinocyte MVP release.
Skin MVP production enhanced by UVB irradiation is consistent with increased
total blood plasma MVP and CaSR-positive blood plasma MVP. CaSR can be
used to mark keratinocyte-derived MVPs in blood, CaSR-positive MVP indicates
that keratinocyte-derived MVP can travel from the skin to the blood circulation.
Keratinocyte-derived MVP carries anti-inflammatory cytokine IL-1ra and bioactive
PAF-R agonistic lipids. Once keratinocyte MVP been released, it interacts with
other cells to transfer its content molecules to mediate systematic biological
responses. Inhibition of MVP release by PAF-R or aSMase deficiency is
associated with inhibited UVB-induced skin inflammation and CHS reaction.
These studies provide the first evidence that targeting MVP release could provide
a potential therapeutic strategy to treat UVB-associated diseases including
sunburn effects and skin cancer.
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